Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-09-04
2007-09-04
Kaushal, Sumesh (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S069100, C435S320100, C435S325000, C435S455000, C530S300000, C530S350000, C530S351000
Reexamination Certificate
active
10104755
ABSTRACT:
Disclosed are various discoveries concerning the angiogenic and angiostatic properties of the CXC chemokines, including the finding that the ELR motif controls the ability of these molecules to induce angiogenesis. Aspects of the invention include, for example, the identification of IP-10, MIG and certain IL-8 analogues as angiostatic agents, and their use in inhibiting angiogenesis in various systems.
REFERENCES:
patent: 5459128 (1995-10-01), Rollins et al.
patent: 5474981 (1995-12-01), Leder et al.
patent: 5728377 (1998-03-01), Sarris et al.
patent: 5739103 (1998-04-01), Rollins et al.
patent: 5824299 (1998-10-01), Luster et al.
patent: 5871723 (1999-02-01), Strieter et al.
patent: 6491906 (2002-12-01), Strieter et al.
Green FH, Overview of Pulmonary Fibrosis Chest. 122(6 ):334S-339S, 2002.
Lindell et al Idiopathic Pulmonary Fibrosis Am J Nurs. 103(4):32-42; 2003.
Zuo et al Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans Zuo et al Proc Natl Acad Sci U S A. 99(9):6292-7, 2002.
Gauldie et al, A new direction in the pathogenesis of Idiopathic Pulmonary Fibrosis? Respir Res. (1):1-3, 2002.
Selman et al Idiopathic Pulmonary Fibrosis: an epithelial/fibroblst cross-talk diorder Respir Res.3(1):1-8, 2002.
Kelly et al Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm 9(1):39-49, 2003.
Ngo, Computational complexity Protein structure prediction and the Levinthal paradox in The Protein Folding Problem and Tertiary Structure Prediction, Merz et al. (eds.), Birkhauser Boston: Boston, MA, pp. 433 and 492-495, 1994).
Rudinger Characteristics of amino acids as components of a peptide hormone sequence (in Peptide Hormones, Parsons (ed.), University Park Press: Baltimore, MD, pp. 1-7, 1976).
Angiolillo et al., “Human Interferon-Inducible Protein 10 is a Potent Inhibitor of Angiogenesis In Vivo,”The Journal of Experimental Medicine, 182:155-162, Jul. 1995.
Anisowicz et al., “Constitutive Overexpression of a Growth-Regulated Gene in Transformed Chinese Hamster and Human Cells,”Proc. Natl. Acad. Sci. USA, 84:7188-7192, Oct. 1987.
Anisowicz et al., “Functional Diversity ofgroGene Expression in Human Fibroblasts and Mammary Epithelial Cells,”Proc. Natl. Acad. Sci. USA, 85:9645-9649, Dec. 1988.
Arenberg et al., “C-X-C Chemokines Display Disparate Angiogenic Activity,”FASEB J., 9:A587, 1995.
Arenberg et al., “The Role of C-X-C Chemokines in Tumor Derived Angiogenesis,”Am. J. Respir. Crit. Care Med., 151:A211, 1995.
Baggiolini et al., “Interleukin-8 and Related Chemotactic Cytokines—CXC and CC Chemokines,”Advances in Immunology, 55:97-179, Jun. 1993.
Beall et al., “Conversion of Monocyte Chemoattractant Protein-1 into a Neutrophil Attractant by Substitution of Two Amino Acids,”The Journal of Biological Chemistry, 267(5) :3455-3459, 1992.
Brandt et al., “A Novel Molecular Variant of the Neutrophil-Activating Peptide NAP-2 with Enhanced Biological Activity is Truncated at theC-Terminus: Identification by Antibodies with Defined Epitope Specificity,”Molecular Immunology, 30(11) :979-991, 1993.
Burdick et al., “Human Bronchogenic Carcinoma Angiogenesis is Mediated by Tumor-Derived Interleukin-8,”FASEB J., 8(4), Mar. 1994, Abstract 849.
Cerretti et al., “Molecular Characterization of Receptors for Human Interleukin-8, GRO/Melanoma Growth-Stimulatory Activity and Neutrophil Activating Peptide-2,”Molecular Immunology, 30(4) :359-367, 1993.
Chomarat et al., “Interferon γ Inhibits Interleukin 10 Production by Monocytes,”J. Exp. Med., 177:523-527, Feb. 1993.
Clark-Lewis et al., “Platelet Factor 4 Binds to Interleukin 8 Receptors and Activates Neutrophils When its N Terminus is Modified with Glu-Leu-Arg,”Proc. Natl. Acad. Sci. USA, 90:3574-3577, 1993.
Clark-Lewis et al., “Structure-Activity Relationships of Interleukin-8 Determined Using Chemically Synthesized Analogs,”The Journal of Biological Chemistry, 266(34) :23128-23134, 1991.
Clore et al., “Three-Dimensional Structure of Interleukin 8 in Solution,”Biochemistry, 29:1689-1696, 1990.
D'Andrea et al., “Interleukin 10 (IL-10) Inhibits Human Lymphocyte Interferon γ-Production by Suppressing Natural Killer Cell Stimulatory Factor/IL-12 Synthesis in Accessory Cells,”J. Exp. Med., 178:1041-1048, Sep. 1993.
Dewald et al., “IP-10, a γ-Interferon-Inducible Protein Related to Interleukin-8, Lacks Neutrophil Activating Properties,”Immunology Letters, 32:81-84, 1992.
Farber, “A Macrophage mRNA Selectively Induced by γ-Interferon Encodes a Member of the Platelet Factor 4 Family of Cytokines,”Proc. Natl. Acad. Sci. USA, 87:5238-5242, 1990.
Farber, “HuMIG; A New Human Member of the Chemokine Family of Cytokines,”Biochemical and Biophysical Research Communications, 192 (1) :223-230, Apr. 1993.
Fivenson et al., “Biological Wound Dressings Function as a Reservoir for C-X-C Chemokines in Chronic Venous Ulcer Therapy,”Clin. Res., 42:232A, 1994.
Gastl et al., “Interleukin-10 Production by Huamn Carcinoma Cell Lines and its Relationship to Interleukin-6 Expression,”Int. J. Cancer, 55:96-101, 1993.
Gronenborn and Clore, “Modeling the Three-Dimensional Structure of the Monocyte Chemo-Attractant and Activating Protein MCAF/MCP-1 on the Basis of the Solution Structure of Interleukin-8,”Protein Engineering, 4(3) :263-269, 1991.
Han et al., “Inhibitory Effect of Platelet Factor 4 (PF4) on the Growth of Human Erythroleukemia Cells: Proposed Mechanism of Action of PF4,”J. Lab. Clin. Med., 120(4) :645-660, Oct. 1992.
Haskill et al., “Identification of Three Related HumanGROGenes Encoding Cytokine Functions,”Proc. natl. Acad. Sci. USA, 87:7732-7736, Oct. 1990.
Hébert et al., “Scanning Mutagenesis of Interleukin-8 a Cluster of Residues Required for Receptor Binding,”The Journal of Biological Chemistry, 266(28) :18989-18994, 1991.
Hu et al., “Interleukin-8 Stimulates Angiogenesis in Rats,”Inflammation, 17(2) :135-143, 1993.
Iida and Grotendorst, “Cloning and Sequencing of a NewgroTranscript from Activated Human Monocytes: Expression in Leukocytes and Wound Tissue,”Molecular and Cellular Biology, 10(10) :5596-5599, Oct. 1990.
Jaffe et al., “Expression of Three Forms of Melanoma Growth Stimulating Activity (MGSA) /gro in Human Retinal Pigment Epithelial Cells,”Investigative Ophthalmology&Visual Science, 34(9) :2776-2785, 1993.
Koch et al., “Interleukin-8 as a Macrophage-Derived Mediator of Angiogenesis,”Science, 258:1798-1801, Dec. 1992.
LaRosa et al., “Amino Terminus of the Interleukin-8 Receptor is a Major Determinant of Receptor Subtype Specificity,”The Journal of Biological Chemistry, 267(35) :25402-25406, 1992.
Lindley et al., “Synthesis and Expression inEscherichia coliof the Gene Encoding Monocyte-Derived Neutrophil-Activating Factor: Biological Equivalence Between Natural and Recombinant Neutrophil-Activating Factor,”Proc. Natl. Acad. Sci. USA, 85:9199-9203, Dec. 1988.
Luster and Ravetch, “Genomic Characterization of a Gamma-Interferon-Inducible Gene (IP-10) and Identification of an Interferon-Inducible Hypersensitive Site,”Molecular and Cellular Biology, 7(10) :3723-3731, Oct. 1987.
Luster et al., “γ-Interferon Transcriptionally Regulates an Early-Response Gene Containing Homology to Platelet Proteins,”Nature, 315:672-676, Jun. 1985.
Luster and Ravetch, “Biochemical Characterization of a γ Interferon-Inducible Cytokine (IP-10),”J. Exp. Med., 166:1084-1097, Oct. 1987.
Luster and Leder, “IP-10, a -C-X-C- Chemokine, Elicits a Potent Thymus-Dependent Antitumor Response In Vivo,”J. Exp. Med., 178:1057-1065, Sep. 1993.
Luster et al., “The IP-10 Chemokine Binds to a Specific Cell Surface Hepar
Kunkel Steven L.
Strieter Robert M.
Kaushal Sumesh
Marshall & Gerstein & Borun LLP
The Regents of The University of Michigan
LandOfFree
Treatment of idiopathic pulmonary fibrosis using IP-10 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of idiopathic pulmonary fibrosis using IP-10, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of idiopathic pulmonary fibrosis using IP-10 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3769313